WaveMan
WaveMan · Company
ELUT · Elutia Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELUT Elutia (ELUT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001708527
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · no price filed

Elutia insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for ELUTIA INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
RAKIN KEVIN
Director
BUY
2026-02-02 SECtraded 2026-01-30
70,000
$74.2K
-18.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 35.7% of the 196,120 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RAKIN KEVIN bought about $74.2K of ELUT on Jan 30, 2026; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
NEELS GUIDO J
Director
BUY
2026-02-02 SECtraded 2026-01-30
20,000
$20.8K
-18.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 29, 2026.
  • -4.8% median (-4.8% mean) 90-day return after 2 previous buys.
  • The trade is 16.8% of the 118,750 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NEELS GUIDO J bought about $20.8K of ELUT on Jan 30, 2026; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
NEELS GUIDO J
Director
BUY
2026-01-29 SEC
15,000
$15.9K
-24.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 28, 2026.
  • The trade is 15.2% of the 98,750 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NEELS GUIDO J bought about $15.9K of ELUT on Jan 29, 2026; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
NEELS GUIDO J
Director
BUY
2026-01-29 SECtraded 2026-01-28
15,000
$15.9K
-24.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 17.9% of the 83,750 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NEELS GUIDO J bought about $15.9K of ELUT on Jan 28, 2026; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
HighCape Partners GP II, LLC
Director
BUY
2025-12-19 SECtraded 2025-12-17
50,000
$26.0K
+45.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.5% of the 322,419 shares held after it.
  • 4 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HighCape Partners GP II, LLC bought about $26.0K of ELUT on Dec 17, 2025; 4 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 20 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
-15.0% year over year
below 68% of Pharma & Biotech
Margin
434.2% net margin
more than 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ELUT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-11.9%12M
-44%-18%+8%+35%2025-102025-122026-022026-042026-062026-082026-10 2026-01-30 · RAKIN KEVIN bought $74.2K2025-12-17 · Ferguson Matthew bought $31.8K2025-12-17 · HighCape Partners GP II, LLC bought $26.0K2026-01-30 · NEELS GUIDO J bought $20.8K2026-01-28 · NEELS GUIDO J bought $15.9K2026-01-29 · NEELS GUIDO J bought $15.9K2025-12-17 · Makes Brigid bought $13.0K2025-11-17 · Colpman David bought $11.5K2025-12-17 · Colpman David bought $6.4K2025-11-13 · Mills C Randal bought $3.8K2025-11-13 · Mills C Randal bought $3.7K2025-12-02 · Ferguson Matthew bought $3.7K2025-11-24 · Mills C Randal bought $3.0K2025-12-01 · Ferguson Matthew bought $2.9K2025-11-13 · Mills C Randal bought $2.7K2025-12-17 · Mills C Randal bought $1.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELUT: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
6,369,894 sh
$6.2M
AIGH Capital Management LLC
2,695,644 sh
$2.6M
Knollwood Investment Advisory, LLC
2,556,724 sh
$2.5M
SILVERARC CAPITAL MANAGEMENT, LLC
2,192,980 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
1,142,575 sh
$1.1M

Congress trades in ELUT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ELUT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ELUT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$114.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$7.4K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$172.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$232.2K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$17.1K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$881.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
-$1.2M
$717.9K
-31%
n/a
2024
$4.5M
$5.1M
$1.7M
+73%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ELUT financials

Revenue growth
-15.0%
XBRL, annual
Net margin
434.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$46.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.66x
long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end); equity 2026-06-30
Cash flow to debt
-1.69x
TTM operating cash flow over long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
+133.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-281.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
0.80x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$12.3M$24.4M$24.7M$49.2M
Gross profit$6.6M$6.7M$11.1M$11.6M
Operating income-$26.9M-$30.7M-$30.5M-$35.2M
Net income$53.4M-$53.9M-$37.7M-$32.9M
EPS (diluted)0.87-1.86-2.07-2.38
Operating cash flow-$44.8M-$22.7M-$21.8M-$21.4M
Cash$36.4M$13.2M$19.3M$17.0M
Long-term debtn/a$22.6M$20.4M$24.3M
SEC XBRL, fiscal years, as known on 2026-10-28

ELUT Stock Sonar score 5/7 axes

Find similar shapesCompare

ELUT ranks highest on risk and compliance (83rd percentile) and profitability (52nd), and lowest on institutional and government (29th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
52
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets+133.7% · 99 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-281.8% · 6 pct, sector of 576
Financial health
29
Inputs
  • Debt to equity1.66x · 12 pct, sector of 352
  • Cash flow to debt-1.69x · 46 pct, sector of 371
Growth
32
Inputs
  • Revenue growth, YoY-15.0% · 32 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
29
Inputs
  • Funds adding, latest quarter17 · 29 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
83
Inputs
  • Short interest, % of float+0.0% · 95 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.0% · 71 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies